Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

Plain-language summary

This study investigates the factors that determine response to BTK degrader drugs in patients with chronic lymphocytic leukemia, through sample collection and analysis. It is open to patients who are candidates for, or have been treated with, BTK degraders. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Nantes University Hospital

Intervention

Non-Interventional Sample Collection and Analysis

Start date

10/9/2025

Estimated completion

9/15/2039

Countries

France

Related genes

Locations

• Angers, France
• Bordeaux, France
• Bordeaux, France
• Clermont-Ferrand, France
• La Roche-sur-Yon, France
• Lyon, France
• Marseille, France
• Montpellier, France
• Nancy, France
• Nantes, France
• Paris, France
• Paris, France
• Poitiers, France
• Rouen, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patient with CLL candidates ou exposed to BTKd
* Patient who has provided informed consent to participate in the study.
* Patient covered by a social security health insurance plan

Exclusion Criteria:

* Minor patients.
* Adults under guardianship.
* Protected persons.